Amerikanische Gesellschaft für Hirudotherapie

Arterial antithrombotic effect of piyavit, the novel pharmacological preparation from the medicinal leech, and of its components, prostanoids and enzyme destabilase

Pharmacology article published in Thrombosis Research (1995)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Speichel-PharmakologieArzneimittelentwicklungBaskova IP, Aguejouf OM, Azougagh-Oualane F, Zavalova LL, Basanova AV, Doutremepuich C · Thrombosis research, 1995

Abstract

Piyavit, the novel pharmacological preparation from the medicinal leech (Hirudo medicinalis) contained the leech saliva, produces the potent arterial antithrombotic effect examined on experimental of Laser Induced Thrombus formation. Administrated orally into rats or injected subcutaneously as water extract, non-diluted or in 1600 times diluted, it inhibits statistically significant comparing with control platelet thrombus stimulated by laser beams. Its components, prostanoid fraction and purified enzyme destabilase, endo-epsilon-(gamma-Glu)-Lys-isopeptidase, also inhibit thrombus formation in statistically different manner, comparing with control. All the tested preparations inhibit platelet aggregation induced by ADP. The dependence of arterial antithrombotic effect on the leech prostanoid is discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdministration, OralAnimalsArteriesBiological FactorsDisease Models, AnimalEndopeptidasesFibrinFibrinolytic AgentsInjections, IntravenousInjections, SubcutaneousLasersLeeches

Zusammenfassung

Oral or subcutaneous piyavit (a leech-saliva pharmacological preparation) and its purified prostanoid and destabilase components inhibit laser-induced rat arterial thrombosis with statistical significance versus control.

Warum dies für die Hirudotherapie relevant ist

This study evaluated the arterial antithrombotic effect of piyavit, a pharmacological preparation from the medicinal leech Hirudo medicinalis containing leech saliva components, using a laser-induced thrombosis model in rats. Piyavit was administered orally or subcutaneously (as a water extract, diluted or undiluted), and its components — a prostanoid fraction and purified destabilase — were also tested; all preparations significantly inhibited platelet thrombus formation and ADP-induced platelet aggregation compared to controls. For ASH's domain, this work is relevant as it examines leech-derived bioactive substances with antithrombotic properties, supporting pharmacological interest in the leech secretome. The study is limited to an animal thrombosis model, and the abstract does not provide human clinical data, detailed dosing, safety outcomes, or comparative efficacy data, and does not involve live hirudotherapy.

Zitation

Arterial antithrombotic effect of piyavit, the novel pharmacological preparation from the medicinal leech, and of its components, prostanoids and enzyme destabilase.

Baskova IP, Aguejouf OM, Azougagh-Oualane F, Zavalova LL, Basanova AV, Doutremepuich C · Thrombosis research, 1995

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.